Patients with clear cell renal cell carcinoma (ccRCC) face a high risk of recurrence after surgery, but existing clinical tools based on clinicopathological factors or costly molecular profiling often lack precision and clinical feasibility….
Continue Reading
Verily, Alphabet’s health data and AI subsidiary, has been awarded a $14.7 million research grant from the Michael J. Fox Foundation (MJFF) for Parkinson’s research to generate a detailed molecular dataset of Parkinson’s disease.The…
Continue Reading
Biotechnology and precision medicine company Caris Life Sciences announced it raised $168 million in growth capital funding.Caris Life Sciences has now raised $1.86 billion in capital since 2018.
Braidwell LP led the round with participation…
Precision medicine is revolutionizing healthcare – by optimizing the efficiency and therapeutic benefit for particular groups of patients, especially by using genetic or molecular profiling. This approach enables a range of health disciplines, including…
Continue Reading
What You Should Know:
Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionise healthcare and improve the human condition using molecular science…
Continue Reading
Cancer therapies have proliferated over the past few decades, improving outcomes for many patients. But this variety requires accurate diagnostics and appropriate decision making to choose the optimal course of therapy. The current gold…
Continue Reading
